期刊
ACS INFECTIOUS DISEASES
卷 7, 期 11, 页码 3025-3033出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.1c00262
关键词
malaria; nonfalciparum; Plasmodium malariae; ex vivo culture; drug discovery
资金
- European and Developing Countries Clinical Trials Partnership (EDCTP) [TMA2017CDF-1892-HypnoBio]
- Medicines for Malaria Venture [RD-18-0067]
The absence of an in vitro cultivation system for Plasmodium malariae makes it difficult to evaluate antimalarial drugs targeting its asexual blood stages. Despite the effectiveness of artemisinin combination therapies on P. falciparum, the increasing detection of P. malariae in malaria-endemic countries poses a challenge.
In vitro and ex vivo cultivation of Plasmodium (P) falciparum has facilitated active research into the malaria parasite toward the quest for basic knowledge and the discovery of effective drug treatments. Such a drug discovery program is currently difficult for P. malariae simply because of the absence of in vitro and ex vivo cultivation system for its asexual blood stages supporting antimalarial evaluation. Despite availability of artemisinin combination therapies effective on P. falciparum, P. malariae is being increasingly detected in malaria endemic countries. P. malariae is responsible for chronic infections and is associated with a high burden of anemia and morbidity. Here, we optimized and adapted ex vivo conditions under which P. malariae can be cultured and used for screening antimalarial drugs. Subsequently, this enabled us to test compounds such as artemether, chloroquine, lumefantrine, and quinine for ex vivo antimalarial activity against P. malariae.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据